Cover Image
市場調查報告書

V503(人類乳突病毒(HPV)預防疫苗)- 預測與市場分析

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 307136
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
V503(人類乳突病毒(HPV)預防疫苗)- 預測與市場分析 V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 69 Pages
簡介

人類乳突病毒(HPV)最初的預防接種疫苗是在2006年開始使用的。全球HPN疫苗市場雖然目前已經確立,但在年輕女性這個傳統目標總族群的接種率依舊不高。當初HPN疫苗是針對子宮頸癌所開發、並上市的預防疫苗,但近年來由於HPV在其它癌症的作用日益解明,部分國家已經開始包括男性、廣泛地獎勵各階層接種疫苗。

本報告提供人類乳突病毒(HPV)疫苗──V503調查分析,提供您疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 疫苗接種獎勵與接種率

  • 接種獎勵概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 未滿足需求和機會

  • 概要
  • 對複數的HPV型的預防
  • 疫苗接種率
  • 疫苗的安全性的認識
  • 人類乳突病毒(HPV)疫苗的認識
  • 人類乳突病毒(HPV)疫苗的價格
  • 用特定層流行的HPV型的接種率
  • 疫苗接種的遵守率
  • 對HPV感染的終身免疫不能獲得
  • 對子宮頸癌檢驗的持續性需求

第7章 開發平台評估

  • 概要
  • 臨床開發中的有潛力疫苗

第8章 V503

  • 概要
  • 功效
  • 安全性
  • 給藥·處方
  • 潛在的臨床的地位
  • 潛在的商業的地位
  • 價格與回本
  • SWOT分析
  • 預測

第9章 附錄

圖表

目錄
Product Code: GDHC388DFR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Merck is developing V503, a nine-valent HPV vaccine; like Gardasil, this vaccine is being developed in partnership with CSL, from which Merck is licensing VLP technology. Both V503 and Merck's current vaccine Gardasil have a similar mechanism of action, consisting of VLPs combined with aluminum salt adjuvant, delivered as an IM injection over a three-dose course. Merck has recently registered a Phase III trial to assess the immunogenicity of V503 given over a two-dose course (Merck, NCT01984697).

Scope

  • Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on V503 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for V503 for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Canada and Australia

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HPV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of V503 performance
  • Obtain sales forecast for V503 from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Canada and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Vaccination Recommendations Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Protection against Multiple HPV Types
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Vaccine Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Perception of Vaccine Safety
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Awareness of HPV Vaccination
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Affordability of HPV Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Coverage of HPV Types Prevalent in Certain Populations
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Vaccine Compliance Rates
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Lifelong Protection from HPV Infection Not Established
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Ongoing Need for Cervical Cancer Screening
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development

8. V503

  • 8.1. Overview
  • 8.2. Immunogenicity
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Individual Drug Assumptions
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Author(s)
    • 9.6.1. Author(s)
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: HPV Vaccine Recommendation Agencies by Country
  • Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
  • Table 5: Marketed Vaccines for HPV, 2014
  • Table 6: Overall Unmet Needs - Current and Future Level of Attainment
  • Table 7: HPV Vaccines - Phase Pipeline, 2014
  • Table 8: Product Profile - V503
  • Table 9: V503 SWOT Analysis, 2013
  • Table 10: Global Sales Forecasts ($m) for V503, 2012-2022
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Back to Top